Neurophet

Neurophet Forward P/E

The Forward P/E Ratio of Neurophet (380550.KQ) as of Oct 27, 2026 is -14.69. In the previous year, Forward P/E Ratio was -21.78 — a change of -32.55% (higher).

Forward P/E

-14.69

YoY

-32.55%

Last updated:

Forward P/E Ratio of Neurophet is 2025 -14.69 . Forward P/E Ratio of Neurophet was 2024 -21.78 . It decreases by -32.55% higher compared to the previous year.

The Neurophet Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2022
-17.94 KRW
Jan 1, 2023
62.48 KRW
Jan 1, 2024
-21.78 KRW
Jan 1, 2025
-14.69 KRW
The Neurophet Forward P/E history
YEARForward P/EYoY
-14.69-32.55%
-21.78-134.85%
62.48-448.17%
-17.94—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neurophet Stock analysis

What does Neurophet do? Neurophet Inc generates revenue through the development and sale of brain imaging analysis software, including 'Neurophet SCALE PET' for positron emission tomography (PET) image quantitative analysis and 'Neurophet AQUA' for neurodegenerative brain disease diagnosis support. The company also offers therapeutic medical devices and medical artificial intelligence (AI) solutions. Its primary customers are healthcare providers and medical institutions seeking advanced diagnostic tools and AI-driven healthcare technologies. The products are sold directly to hospitals, clinics, and research institutions that require specialized brain imaging and diagnostic support. Neurophet Inc targets the health care technology sector, focusing on neurology and medical imaging applications. The company's revenue streams include software licensing, device sales, and AI solution subscriptions. Neurophet Inc's business model centers on providing innovative medical technology solutions for neurological conditions. The firm's key products address specific clinical needs in neurodegenerative disease diagnosis and PET image analysis, with a focus on accuracy and efficiency for medical professionals. The company's offerings are designed to enhance diagnostic capabilities in healthcare settings. Neurophet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neurophet stock

Forward P/E Ratio of Neurophet is -14.69 in 2025.

Forward P/E Ratio of Neurophet changed from -21.78 to -14.69, representing a -32.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Neurophet since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Neurophet with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Neurophet

All Key Metrics — Neurophet